AG真人官方

DexCom, Inc. (DXCM) Form 144 filing discloses a proposed sale of 1,466 common shares by shareholder Sadie Stern through Morgan Stanley Smith Barney. The shares, valued at $130,459, are expected to be sold on or about 28 Jul 2025 on the NASDAQ. They represent roughly 0.0004 % of DexCom鈥檚 392.1 million shares outstanding, implying minimal market impact.

The shares were acquired as restricted stock on 19 Nov 2023. In the last three months, the same holder completed four sales totaling 7,650 shares for $651,016 in gross proceeds, indicating an ongoing liquidation pattern. No other insiders or financial metrics are disclosed.

The filer affirms awareness of no undisclosed adverse information and notes potential reliance on a Rule 10b5-1 trading plan. Aside from insider-sale data, the filing contains no operational or earnings updates.

On 25 July 2025 ClearSign Technologies (CLIR) convened its Annual Meeting with 37.1 M shares present, representing 70.8% of outstanding voting power.

Proposal 1 鈥� Board elections: All six nominees were re-elected. While Louis J. Basenese, Anthony DiGiandomenico and CEO Colin J. Deller each received >98% of votes cast, Catharine M. de Lacy and Judith S. Schrecker obtained only ~33% support (8.7 M for vs. 17.8 M withheld), indicating meaningful shareholder dissent. Former director David M. Maley stepped down and the board was reduced from seven to six seats.

Proposal 2 鈥� Auditor: Shareholders approved BPM CPA LLP as independent auditor for FY 2025 by 34.0 M for, 3.0 M against (92.0% support).

Proposal 3 鈥� Say-on-Pay: Executive compensation passed with 20.4 M for, 3.9 M against, 2.2 M abstentions (76.2% support).

No additional material events or financial results were disclosed.

Alvotech鈥檚 July 2025 Form 6-K details governance, commercial, regulatory and financing actions since its Q1 report.

• Governance: Six directors re-elected; veteran executive Linda J贸nsd贸ttir appointed CFO; COO Faysal Kalmoua exits board and management.
• Commercial: Advanz Pharma partnership broadened to three new biosimilars (milestones up to 鈧�160 m) and separate AVT10 (Cimzia) deal; global Keytruda biosimilar co-development with Dr. Reddy鈥檚.
• M&A: Acquired Swiss packager Ivers-Lee and Xbrane鈥檚 Swedish R&D team plus Cimzia candidate for c.SEK 275 m.
• Pipeline: CHMP positive opinion for AVT06 (Eylea); AVT23 (Xolair) study shows therapeutic equivalence.
• Manufacturing risk: FDA pre-approval inspection (26 Jun鈥�4 Jul) issued Form 483 citing operational, documentation and quality control deficiencies; detailed response submitted 25 Jul.
• Financing: Oversubscribed SDR IPO (SEK 39 m) and institutional placement (SEK 750 m) add >3,000 new holders; term-loan amendment folds second tranche, trims margin to SOFR+6.0%, facility now $1.081 bn, cash $152 m.

New capital and partnerships enhance growth prospects, but regulatory remediation is critical for near-term BLA approvals.

Datadog, Inc. (DDOG) filed a Form 144 indicating that co-founder and CEO Olivier Pomel intends to sell 11,195 Class A shares through Morgan Stanley. At the 07/28/2025 anticipated execution date, the aggregate market value of the planned sale is $1.68 million. The shares represent roughly 0.0035 % of the company鈥檚 319.5 million shares outstanding and were originally acquired as founder shares on 07/08/2010.

The filing also lists insider sales completed over the prior three months under 10b5-1 plans. In that period, Pomel sold 鈮�363,600 shares across six transactions, generating gross proceeds of 鈮�$44.3 million. The largest single trade was 107,365 shares on 06/09/2025 for $13.07 million. If the newly noticed sale is executed, total shares disposed in the rolling 90-day window would rise to about 374,800.

While the proposed transaction is minor relative to total float, the cumulative volume of recent insider selling may draw investor attention. Because the sales are structured under Rule 144 and disclosed 10b5-1 plans, they do not necessarily signal adverse information, but they do reduce the CEO鈥檚 direct exposure.

Director Dilip S. Vyas has reported the disposal of his entire 32,000-share holding in SigmaTron International Inc. (SGMA) via Form 4 filed 07/28/2025. The shares were tendered on 07/25/2025 at $3.02 per share under transaction code 鈥淯,鈥� indicating acceptance of the cash consideration offered through the Agreement and Plan of Merger dated 05/20/2025 among SigmaTron, Transom Axis AcquireCo, LLC and Transom Axis MergerSub, Inc. At the 鈥淎cceptance Time,鈥� MergerSub accepted all properly tendered shares, including those of the reporting person. Post-transaction beneficial ownership is reported as zero, and no derivative securities were listed. The filing confirms closing steps of the tender offer but provides no additional financial metrics.

On 07/25/2025 SigmaTron International (SGMA) Chief Executive Officer and Director Gary R. Fairhead tendered his entire holding of 103,303 common shares into the cash offer structured under the 05/20/2025 Merger Agreement with Transom Axis AcquireCo and Transom Axis MergerSub. The shares were accepted at $3.02 per share in cash, coded 鈥淯,鈥� which denotes a disposition pursuant to a merger or tender offer. After the transaction the reporting person shows 0 directly owned shares, and no derivative securities are listed.

The Form 4 confirms insider participation in the acquisition鈥檚 tender-offer phase and indicates that the offer was consummated at the 鈥淎cceptance Time鈥� on 07/25/2025. No additional equity or option grants were reported.

SigmaTron International, Inc. (SGMA) filed Post-Effective Amendment No. 1 to seven prior Form S-8 registration statements in connection with its 28 Jul 2025 merger with Transom Axis AcquireCo, LLC. Because the company has been merged into a wholly-owned subsidiary of the acquirer, all employee and director equity incentive offerings have been terminated. The amendment therefore deregis颅ters all shares that were previously registered but remain unsold under the following plans:

• 2021, 2019 & 2013 equity plans 鈥� 1,021,915 shares
• 2011 & 2004 plans 鈥� 450,000 shares
• 2000 plans 鈥� 560,000 shares
• 1997 plan 鈥� 105,000 shares
• 1994 & 1993 plans 鈥� shares previously registered (exact count not restated)

In aggregate, more than 2.1 million unsold shares of common stock are being withdrawn from registration. The filing formally terminates the effectiveness of all seven registration statements and requires no additional signatures under Rule 478.

SigmaTron International, Inc. (SGMA) filed Post-Effective Amendment No. 1 to seven prior Form S-8 registration statements in connection with its 28 Jul 2025 merger with Transom Axis AcquireCo, LLC. Because the company has been merged into a wholly-owned subsidiary of the acquirer, all employee and director equity incentive offerings have been terminated. The amendment therefore deregis颅ters all shares that were previously registered but remain unsold under the following plans:

• 2021, 2019 & 2013 equity plans 鈥� 1,021,915 shares
• 2011 & 2004 plans 鈥� 450,000 shares
• 2000 plans 鈥� 560,000 shares
• 1997 plan 鈥� 105,000 shares
• 1994 & 1993 plans 鈥� shares previously registered (exact count not restated)

In aggregate, more than 2.1 million unsold shares of common stock are being withdrawn from registration. The filing formally terminates the effectiveness of all seven registration statements and requires no additional signatures under Rule 478.

SigmaTron International, Inc. (SGMA) filed Post-Effective Amendment No. 1 to seven prior Form S-8 registration statements in connection with its 28 Jul 2025 merger with Transom Axis AcquireCo, LLC. Because the company has been merged into a wholly-owned subsidiary of the acquirer, all employee and director equity incentive offerings have been terminated. The amendment therefore deregis颅ters all shares that were previously registered but remain unsold under the following plans:

• 2021, 2019 & 2013 equity plans 鈥� 1,021,915 shares
• 2011 & 2004 plans 鈥� 450,000 shares
• 2000 plans 鈥� 560,000 shares
• 1997 plan 鈥� 105,000 shares
• 1994 & 1993 plans 鈥� shares previously registered (exact count not restated)

In aggregate, more than 2.1 million unsold shares of common stock are being withdrawn from registration. The filing formally terminates the effectiveness of all seven registration statements and requires no additional signatures under Rule 478.